STAT

When can we let up? Health experts craft strategies to safely relax coronavirus lockdowns

Experts are starting to figure out how smarter, targeted approaches could serve as an off-ramp for the current strict #coronavirus control measures.
An empty schoolyard in San Francisco.

With countries from Italy to the U.S. having waited too long to combat the coronavirus, many experts in public health and epidemiology are pleading with government officials not to compound the mistake by lifting stay-at-home and other social distancing measures too soon — and, in fact, to impose strict ones in U.S. states and cities that haven’t.

But from the World Health Organization to New York Gov. Andrew Cuomo to epidemiology modelers across the globe, there is growing recognition that the time will and must come to tiptoe back toward normalcy.

That recognition is driving the next life-and-death questions in the coronavirus pandemic: What is the exit strategy? How will we know when it’s safe to implement it? If this first wave of outbreak eventually crests and dissipates, as it has in China, what’s the plan if the virus returns with a vengeance in a few months? Can that plan be less disruptive to livelihoods and ordinary existence than the panicked responses in many western countries over the last month, and more like the surgical strikes that seem to have succeeded in Singapore and South Korea?

The “when can we?” research, unfortunately, is playing out against a highly politicized background. President Trump on Tuesday vowed to return the country to “normal” by Easter, April 12. But while the epidemic in the U.S. is still far from under control, much less peaking, apolitical experts are nevertheless cautiously starting to figure out how smarter, targeted approaches could serve as an off-ramp for the current control measures and how to do better next time, especially if Covid-19 cases rebound

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min readChemistry
STAT+: Pharmalittle: We’re Reading About Fake Studies, AbbVie Investing In Psychedelics, And More
Fake studies have flooded publishers of top scientific journals,. leading to thousands of retractions and millions of dollars in lost revenue.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks